[ad_1]
Vancouver, Canada, Feb. 07, 2022 (GLOBE NEWSWIRE) —
- Post-operative infections occur in up to 300,000 patients per year in the United States and cost the US healthcare system tens of billions of dollars a year. [1]
Ondine Biomedical Inc. (LON: OBI), has treated the first patient in its nasal photodisinfection exploratory Phase 2 trial. The study will evaluate how effectively the treatment eradicates pathogens – Staphylococcus aureus – in the nose, and the occurrence of surgical site infections (SSIs) within 30 days of surgery.
The single-center, BENEFIT-ADPT open-label study is being carried out at HCA Healthcare’s Memorial Health University Medical Center in Savannah, Georgia and will involve up to 500 surgical patients.
Carolyn Cross, Ondine’s CEO commented, “We are delighted to be able to initiate this important study with the team at HCA Healthcare’s Memorial Health University Medical Center. We are particularly pleased to start treating patients in light of the Omicron challenges, which have strained hospital resources and impacted clinical trials around the world. We appreciate HCA’s support and the importance they place on reducing SSIs. This is a truly novel approach to nasal disinfection, and we believe that our technology has the …
Full story available on Benzinga.com
[ad_2]
Source link
